Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Cerilliant
Fish and Richardson
US Army
McKesson
Novartis
US Department of Justice
QuintilesIMS
Baxter
Daiichi Sankyo

Generated: August 16, 2017

DrugPatentWatch Database Preview

evzio Drug Profile

« Back to Dashboard

Which patents cover Evzio, and when can generic versions of Evzio launch?

Evzio is a drug marketed by Kaleo Inc and is included in two NDAs. There are twenty-three patents protecting this drug.

This drug has one hundred and thirty patent family members in fifteen countries.

The generic ingredient in EVZIO is naloxone hydrochloride. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

Summary for Tradename: evzio

Patents:23
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list20
Patent Applications: see list5,147
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:evzio at DailyMed

Pharmacology for Tradename: evzio

Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kaleo Inc
EVZIO
naloxone hydrochloride
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Kaleo Inc
EVZIO
naloxone hydrochloride
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Kaleo Inc
EVZIO
naloxone hydrochloride
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Kaleo Inc
EVZIO
naloxone hydrochloride
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Kaleo Inc
EVZIO
naloxone hydrochloride
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EVZIO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,172,082Devices, systems and methods for medicament delivery► Subscribe
9,327,077Medical injector with compliance tracking and monitoring► Subscribe
9,022,980Medical injector simulation device► Subscribe
7,416,540Devices systems and methods for medicament delivery► Subscribe
8,932,252Medical injector simulation device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EVZIO

Country Document Number Estimated Expiration
Mexico2007009152► Subscribe
World Intellectual Property Organization (WIPO)2010056712► Subscribe
New Zealand555256► Subscribe
Israel227617► Subscribe
World Intellectual Property Organization (WIPO)2008081446► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EVZIO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Novartis
Express Scripts
Fish and Richardson
Boehringer Ingelheim
Dow
Covington
Teva
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot